tarlatamab

all catalysts(2)

News(8)

• Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
  The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.
  biopharma_dive · 6d ago
• Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
  Daiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.
  fiercebiotech · 7d ago
• China’s Henlius carves out $440M T-cell engager deal with Amberstone
  Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers.
  fiercebiotech · 10d ago
• Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
  MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…
  fiercebiotech · 21d ago
• Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
  Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…
  biopharma_dive · 23d ago
• GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
  GSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.
  fiercebiotech · 24d ago
• Amgen’s T cell engager notches new major lung cancer victory
  Amgen reported a key clinical win for its T cell engager platform, finding that Imdelltra combined with a checkpoint inhibitor helped patients with advanced lung cancer live longer. The California…
  endpoints · 26d ago
• New data could widen use of AstraZeneca, Amgen immune disease drug
  Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
  biopharma_dive · 1mo ago